Eurobio Scientific S.A.
ALERS.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -647.10 | 0.23 | 0.37 |
| FCF Yield | 0.00% | 2.88% | 4.24% | 9.27% |
| EV / EBITDA | 0.00 | 33.12 | 16.49 | 14.62 |
| Quality | ||||
| ROIC | 0.00% | -0.15% | 1.69% | 1.42% |
| Gross Margin | 47.04% | 44.75% | 45.40% | 43.03% |
| Cash Conversion Ratio | – | -8,991.00 | 1.93 | 5.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.71% | 4.80% | 22.74% | 36.91% |
| Free Cash Flow Growth | -100.00% | 24.53% | -57.12% | 89.08% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 1.50 | 4.20 | 3.71 |
| Interest Coverage | 2.76 | 3.37 | 3.17 | 2.81 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.68 | 1.71 | 1.89 |
| Cash Conversion Cycle | 0.00 | 59.70 | 43.75 | 45.82 |